Editorial illustration of frontotemporal dementia imaging, intranasal spray delivery, and three-arm clinical trial design. Credit: CellXperience generated editorial illustration.
Frontotemporal dementia is not the first disease people usually name when they talk about regenerative medicine. That is part of why this new trial record is worth a closer read.
ClinicalTrials.gov first posted NCT07638813 on June 10, 2026. The record was updated on July 13 and currently lists the study as not yet recruiting, with status verified in July 2026. Ruijin Hospital is the lead sponsor, ECHO Biotech is listed as a collaborator, and the planned enrollment is 33 participants.
The official title is direct: a randomized, double-blind, placebo-controlled trial of umbilical-cord mesenchymal stem cell-derived exosomes, given intranasally, in patients with frontotemporal dementia.
That makes the record interesting for two reasons at once. It is an MSC-exosome program in a neurodegenerative disease with no easy disease-modifying path. It is also a small Phase 1/2 study that puts route, dose, placebo, masking, safety, and a named FTD clinical scale into the public record before recruitment begins.
What the trial is actually testing
The product is described as human umbilical-cord mesenchymal stem cell-derived exosomes. The route is intranasal spray. The schedule is twice weekly for 24 consecutive weeks.
There are three study arms.
The placebo group receives normal saline, 1 mL per administration, twice weekly for 24 weeks. The registry says the placebo is identical in appearance, packaging, and administration procedure to the active product.
The low-dose group receives 1 mL of MSC-derived exosomes containing 24 x 10^9 particles per administration, twice weekly for 24 weeks.
The high-dose group receives 1 mL containing 36 x 10^9 particles per administration, twice weekly for 24 weeks. The high-dose arm begins only after the first three low-dose participants complete a four-week safety lead-in without dose-limiting toxicity or serious adverse events.
That sequence matters. It gives the trial a small safety gate before the higher dose is opened. For an intranasal exosome program, the dose units, dosing rhythm, placebo procedure, and escalation logic are the practical details to keep in view.
The masking is meaningful
The ClinicalTrials.gov record lists randomized allocation, parallel assignment, and triple masking. Participants, care providers, and outcome assessors are masked.
That matters in FTD because many outcomes depend on clinical assessment, caregiver report, behavior, language, and day-to-day function. If assignment becomes obvious, interpretation gets harder quickly.
The placebo design helps. A normal-saline nasal spray with matching appearance, packaging, and administration procedure is a cleaner comparator than usual care or a loosely defined control. It does not solve every problem in a small neurodegenerative-disease trial, but it gives the study a clearer starting point.
This is especially important because the treatment route is patient-friendly on the surface. Intranasal dosing sounds simple compared with brain delivery or intrathecal administration. The clinical question is not whether nasal spray is convenient. The question is whether this specific product, dose, schedule, and patient population can produce a measurable effect while remaining tolerable.
The endpoint is an FTD endpoint, not a generic dementia endpoint
The primary clinical outcome is change from baseline in the CDR plus NACC FTLD total score at Week 24. The registry gives a scale range of 0 to 30, with higher scores indicating worse cognitive and behavioral function.
That endpoint choice is important because FTD is not Alzheimer’s disease with a different name. Behavioral variant FTD, semantic variant primary progressive aphasia, and non-fluent variant primary progressive aphasia can look very different in clinic. A trial that relies only on broad cognitive screening would miss too much of the disease.
The inclusion criteria reflect that. The record allows probable FTD, including behavioral variant FTD, semantic variant PPA, or non-fluent variant PPA, with supportive CT or MRI evidence of frontal and/or temporal lobe atrophy. Participants must be 30 to 80 years old, have an FTLD-CDR score of 0 to 2, and have MMSE greater than 10 at screening. A study partner is required, with at least three hours of daily care or visits and ability to manage study medication.
Those details make the trial more readable. The population is not just "dementia." It is FTD with imaging support, a defined severity window, and a caregiver structure for follow-up.
Safety sits near the center of the design
The record lists safety and tolerability as a co-primary focus through Week 24. It tracks treatment-emergent adverse events, serious adverse events, adverse drug reactions, and serious adverse drug reactions, including causality and severity.
The listed events include local nasal reactions such as epistaxis, nasal congestion, rhinorrhea, cough, pharyngeal discomfort, sneezing, and nasal dryness. It also includes systemic reactions such as rash, pruritus, facial or eyelid swelling, dyspnea, chest tightness, fever, and chills.
That is the right kind of safety language for this route. Intranasal delivery is attractive partly because it avoids invasive CNS administration. It still has to show local tolerability, dosing feasibility over 24 weeks, and no concerning systemic pattern.
The schedule is not trivial either. Twice-weekly dosing for six months asks a lot from patients and caregivers. In FTD, adherence and caregiver burden are part of whether an apparently simple route can work in practice.
The secondary outcomes widen the readout
The secondary outcomes cover global cognition, language, behavior, executive function, and daily function. The registry lists MMSE and MoCA for global cognition, Boston Naming Test and semantic fluency for language, Neuropsychiatric Inventory and Frontal Behavior Inventory for behavioral symptoms, Frontal Assessment Battery for executive function, and an ADL measure for daily function.
That is a broad readout panel for 33 planned participants. It may help the study describe where any movement appears: cognition, language, behavior, executive function, or daily living. It also means the eventual interpretation will need restraint. A small study with many secondary measures can generate interesting patterns before it generates a durable answer.
The exploratory imaging outcomes are also worth noting. The record lists regional brain volume by structural MRI and resting-state functional connectivity by fMRI. In FTD, that makes sense. The disease is anatomically visible, and a therapy claim becomes more coherent if clinical change and brain measures can be read together.
But imaging should not be treated as decoration. If the trial eventually reports clinical movement without any interpretable structural or functional imaging context, the result will be harder to place. If imaging changes appear without a clinical pattern, that will raise a different set of questions.
The route is a serious bet
Intranasal delivery is one of the more attractive routes for CNS-directed extracellular-vesicle programs. It is noninvasive, repeatable, and easier to imagine in a chronic disease than surgery. The registry summary says the route may allow treatment to reach the brain without needing to pass through the blood-brain barrier in the usual way.
That hypothesis is exactly what the trial has to test.
The future readout will need to connect several pieces: product identity, particle dose, dosing schedule, nasal tolerability, clinical scale movement, caregiver-informed outcomes, and, ideally, imaging or biological measures that make the direction of change easier to understand.
This is why the record is more interesting than a short exosome announcement. It gives enough structure to follow the program as recruitment, dosing, safety, and Week 24 outcomes develop.
What would make this trial important
The first milestone is recruitment. As of the current ClinicalTrials.gov record, the study is not yet recruiting despite an estimated July 1, 2026 start date. A recruitment update will matter because the patient population is specific and requires a study partner.
After that, the safety lead-in matters. The high-dose arm only opens after the first three low-dose participants complete four weeks without dose-limiting toxicity or serious adverse events. That is a small gate, but it is a real one.
The Week 24 readout will be the first meaningful public test of the design. The CDR plus NACC FTLD result should be read together with safety, adherence, study completion, behavioral measures, language measures, executive-function measures, and imaging. A clean safety profile with a coherent pattern across FTD-relevant outcomes would be a stronger step than an isolated secondary change.
At this stage, the public record is enough to justify attention. It puts intranasal MSC-derived exosomes into a defined FTD trial with placebo, masking, two dose levels, a safety lead-in, and a disease-relevant primary clinical scale.
That is a serious enough design to follow. The field can ask for results later. Today, the useful fact is that the question has been written down clearly.
Key source
- ClinicalTrials.gov NCT07638813, "MSC-Exosome Therapy for Frontotemporal Dementia" - https://clinicaltrials.gov/study/NCT07638813